Efavirenz-induced hypersensitivity reaction manifesting in rash and hepatitis in a Latino male

Annals of Pharmacotherapy

Volumn 42, Issue 3, 2008, Pages 425-429

  Leung, Jennifer M ^a   O'Brien, John G ^a,b,c   Wong, Hing Ka ^d   Winslow, Dean L ^e,f  

^a Santa Clara Valley Health & Hospital System   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF THE PACIFIC   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e Valley Health   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Efavirenz; Hepatitis; Hypersensitivity; Nonnucleoside reverse transcriptase inhibitors; Rash

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIEMETIC AGENT; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; AZITHROMYCIN; CLINDAMYCIN; EFAVIRENZ; EMTRICITABINE; FLUCONAZOLE; HYDROXYZINE; PYRIMETHAMINE; RITONAVIR; SULFADIAZINE; TENOFOVIR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMMONIA BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CASE REPORT; DIARRHEA; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ENCEPHALITIS; EPIGASTRIC PAIN; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; MACULOPAPULAR RASH; MALE; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; TOXIC HEPATITIS; VOMITING;

ADULT; BENZOXAZINES; DRUG HYPERSENSITIVITY; EXANTHEMA; HEPATITIS; HISPANIC AMERICANS; HUMANS; MALE;

EID: 41149087265     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K574     Document Type: Article

References (15)

1. Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, December 1, 2007. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf (accessed 2008 Jan 17).
2. Van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine, and lamivudine: a randomised open-label trial, the 2NN study. Lancet 2004;363:1253-63.
3. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002;36:512-3.
4. Kontorinis N, Dieterich D. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 2003;23:173-82.
5. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
6. Package insert. Truvada (tenofovir 300 mg/emtricitabine 200 mg). Foster City, CA: Gilead Sciences, May 2007.
7. ter Hofsteade HJ, de Marie S, Fondraine NA, et al. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS 2000;11:611-6.
8. Abrescia N, D'Abbraccio MD, Figoni M, et al. Fulminant hepatic failure after the start of an efavirenz-based HAART regimen in a treatment-naïve female AIDS patient without hepatitis virus co-infection. J Antimicrob Chemother 2002;50:763-5.
9. Bossi P, Colin D, Bricaire F, Caumes E. Hypersensitivity syndrome associated with efavirenz therapy. Clin Infect Dis 2000;30:227-8.
10. German P, Greenhouse B, Coates C, et al. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin Infect Dis 2007;44:889-90.
11. Package insert. Sustiva (efavirenz). Princeton, NJ: Bristol-Myers Squibb Co., January 2007.
12. Rodriguez-Novoa S, Barrerio P, Rendon A. Influence of 516 G>T polymorphisms at the gene encoding the CYP 450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 2005;40:1358-61.
13. Stahle L, Moberg L, Svensson J, Sonnerborg A. Efavirenz plasma concentrations in HIV-infected patients. Ther Drug Monit 2004;26:267-70.
14. Haas D. Will pharmacogenomic discoveries improve HIV therapeutics? Topics HIV Med 2005;13:90-5.
15. Gutierrez F, Navarro A, Padilla S, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using drug level monitoring. Clin Infect Dis 2005;41:1648-53.